Direct comparison
ICH E6 vs E8(R1): GCP vs Study Design
ICH E6 governs how clinical trials are conducted (GCP); ICH E8(R1) sets the quality-by-design framework used to plan them. How the two relate.
Side-by-side comparison
| Dimension | ICH E6 (GCP) | ICH E8(R1) |
|---|---|---|
| Full title | Good Clinical Practice (GCP) | General Considerations for Clinical Studies |
| Stage of the study lifecycle | Conduct — once the trial is underway | Planning — before the protocol is finalized |
| Central concept | Ethical conduct, participant protection, monitoring, data integrity | Quality by design (QbD); critical-to-quality (CtQ) factors |
| Current core version | E6(R3), ICH Step 4 finalized 6 January 2025 (rolling regional adoption since); E6(R2), 2016 addendum, still operative in many regions during transition | E8(R1), ICH Step 4 finalized 6 October 2021; FDA final guidance 11 April 2022 |
| Original version | E6(R1), 1996 | E8, 1997 |
| Scope of studies covered | Interventional clinical trials specifically | All "clinical studies," including non-interventional and real-world-data designs |
| Primary audience | Investigators, site staff, CRAs/monitors, sponsor QA | Protocol authors, biostatisticians, clinical operations, quality/regulatory affairs |
| Relationship to the other | E6(R3) was restructured to operationalize E8(R1)'s QbD/CtQ framework | Sets the design-stage framework that E6 implements during conduct |
| Does it replace the other? | No — governs a different stage | No — governs a different stage |
Common questions
FAQ
Does ICH E8(R1) replace ICH E6?+
No. They cover different stages of the same study — E8(R1) governs planning and design, E6 governs conduct. A study applies both, not one instead of the other.
Which version of ICH E6 is currently in effect, R2 or R3?+
It depends on the region and the timing of a given study's approval. ICH E6(R3) reached ICH Step 4 on 6 January 2025 and has been adopted on a rolling basis since (EU from July 2025, FDA final guidance September 2025, UK MHRA annotations January 2026); ICH E6(R2) (2016) remains operative in many regions during this transition. Check the relevant regulatory authority's current adoption status for a specific study.
Do site-level investigators and coordinators need to know ICH E8(R1), or is it just for sponsors?+
E8(R1) is primarily applied by the sponsor-side teams who design the protocol and development program — biostatisticians, clinical operations, and quality/regulatory affairs. Site investigators and coordinators generally work from the resulting protocol and GCP (E6) requirements rather than applying E8(R1) directly themselves, though understanding why certain elements were prioritized as critical-to-quality can help site staff prioritize their own attention during conduct.
How does a "critical-to-quality factor" actually show up in a protocol?+
It typically shows up as specific design or monitoring choices the study team made deliberately — for example, extra verification steps around primary endpoint capture, tighter eligibility-screening procedures, or a risk-based monitoring plan that concentrates on the handful of data points and processes identified as critical, rather than applying uniform oversight to everything in the protocol.
